PI3K Inhibitors Are Finally Coming of Age

The authors summarize key discoveries that aid the clinical translation of PI3Kα and PI3Kδ inhibitors, including the PI3Kα isoform-selective inhibitor alpelisib for the treatment of breast cancer, highlighting lessons learnt and future opportunities.